Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 2, 2026, SINTX Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”) pursuant to which the Company agreed to sell in a private placement (the “Offering”) an aggregate of 1,882,845 units (the “Units”) at a purchase price of $2.39 per Unit for aggregate gross proceeds of approximately $4.5 million, before deducting fees and offering expenses. Each Unit consists of: one share of the Company’s common stock, par value $0.01 per share (the “Common Stock”); one Class A Common Stock Purchase Warrant (the “Class A Warrant”); and one Class B Common Stock Purchase Warrant (the “Class B Warrant”). The Purchase Agreement contains customary representations, warranties, covenants and closing conditions by the Company and the Purchasers. The Company also agreed to file a resale registration statement covering the shares of Common Stock sold in the Offering and the shares issuable upon exercise of the warrants pursuant to a Registration Rights Agreement described below. The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. On April 6, 2026, the Company entered into a Confidential and Proprietary Information Agreement (the “Partner Capital Agreement”) with Partner Capital Group, LLC (“Partner Capital”), pursuant to which Partner Capital acted as non-exclusive marketing and consulting representative to represent the Company for an initial three (3) months term from the date of this Agreement (the “Initial Term”) in a potential bona fide capital raising transaction involving the offer and sale of equity, equity-linked or debt securities of the Company to financial investors for the primary purpose of raising capital. Pursuant to the Partner Capital Agreement, the Company agreed to pay Partner Capital a cash placement fee equal to 7% of the aggregate gross proceeds received by the Company from targeted, qualified potential investors identified and introduced in writing during the Initial Term by Partner Capital, together with any other investors that are directly introduced to the Company for a potential investment in the Company and to reimburse certain expenses incurred in connection with the Offering. The Company also agreed to provide customary indemnification and contribution rights to Partner Capital. The Partner Capital Agreement contains customary representations, warranties, covenants and closing conditions of the parties. The foregoing description of the Partner Capital Agreement does not purport to be complete and is qualified in its entirety by reference to the Partner Capital Agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K and incorporated herein by reference. Class A Common Stock Warrants At the closing of the Offering, the Company will issue Class A Warrants to purchase an aggregate of 1,882,845 shares of Common Stock. Each Class A Warrant becomes exercisable upon issuance, has an exercise price equal to $2.14 per share, subject to adjustment as provided therein, and expires on the fifth anniversary of its issuance. The Class A Warrants contain customary anti-dilution adjustments for stock splits, stock dividends and similar events. In addition, subject to compliance with applicable Nasdaq rules and stockholder approval requirements, the exercise price of the Class A Warrants is subject to adjustment if the Company issues Common Stock or Common Stock Equivalents in certain future equity financing transactions at a price below the then-current exercise price. The Class A Warrants also contain customary provisions relating to fundamental transactions, including mergers, consolidations, sales of substantially all assets and similar transactions. Holders may exercise the warrants on a cashless basis under certain circumstances. The Class A Warrants are also subject to beneficial ownership limitations of 4.99% or 9.99%, at the election of the holder. The foregoing description of the Class A Warrants does not purport to be complete and is qualified in its entirety by reference to the form of Class A Common Stock Warrant filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference. Class B Common Stock Warrants At the closing of the Offering, the Company will issue Class B Warrants to purchase an aggregate of 1,882,845 shares of Common Stock. The Class B Warrants are immediately exercisable, have an exercise price of $2.14 per share, subject to adjustment as provided therein, and expire on the second anniversary of the initial exercise date. The Class B Warrants contain customary anti-dilution adjustments for stock splits, stock dividends and similar events. In addition, subject to compliance with applicable Nasdaq rules and stockholder approval requirements, the exercise price of the Class B Warrants is subject to a adjustment if the Company completes certain future equity financings at a price below the then-current exercise price. The Class B Warrants also contain customary provisions relating to fundamental transactions, including mergers, consolidations and sales of substantially all of the Company’s assets. Under certain circumstances, holders may exercise the Class B Warrants on a cashless basis. The Class B Warrants are also subject to beneficial ownership limitations of 4.99% or 9.99%, at the election of the holder. In addition, upon the occurrence of specified revenue milestones, the Company may require holders to exercise all or a portion of their then-outstanding Class B Warrants. Specifically, if the Company reports quarterly revenue of at least $2.0 million in a fiscal quarter, as evidenced in a Quarterly Report on Form 10-Q, Annual Report on Form 10-K, or certain Current Reports on Form 8-K, the Company may deliver a notice requiring the holder to exercise all or a specified portion of the outstanding Class B Warrants within five business days. Any portion of the called warrants not timely exercised would automatically expire without consideration, subject to the warrant’s beneficial ownership limitations. The foregoing description of the Class B Warrants does not purport to be complete and is qualified in its entirety by reference to the form of Class B Common Stock Warrant filed as Exhibit 4.2 to this Current Report on Form 8-K and incorporated herein by reference. Registration Rights Agreement In connection with the Offering, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers. Pursuant to the Registration Rights Agreement, the Company agreed to file with the Securities and Exchange Commission (the “SEC”) a registration statement covering the resale of the shares of Common Stock sold in the Offering and the shares issuable upon exercise of the warrants no later than 30 calendar days following the closing of the Offering and to use its best efforts to cause such registration statement to be declared effective within 60 calendar days after the closing (or 90 calendar days in the event of SEC review). The Company also agreed to use its best efforts to maintain the effectiveness of the registration statement until all registrable securities covered thereby have been sold or may be sold without restriction pursuant to Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”). The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Registration Rights Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.
SINT Sintx Technologies, Inc. - 8-K
Accession
0001493152-26-0269851.013.028.019.01
Item 1.01 - Entry into a Material Definitive Agreement
1,230 words
Item 3.02 - Unregistered Sales of Equity Securities
246 words
Item 3.02 Unregistered Sales of Equity Securities. The disclosure set forth above under Item 1.01 is incorporated herein by reference. On June 2, 2026, the Company entered into a private placement of 1,882,845 Units to accredited investors for aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and offering expenses. Each Unit consisted of one share of Common Stock, one Class A Warrant and one Class B Warrant. The Class A Warrants and Class B Warrants each entitle the holder to purchase one share of Common Stock for each share of Common Stock purchased in the Offering, resulting in aggregate warrant coverage equal to 200% of the shares of Common Stock issued in the Offering. The securities issued in the Offering were offered and sold in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. The Purchasers represented that they were accredited investors, acquired the securities for investment purposes only and not with a view toward distribution, and appropriate restrictive legends were placed on the securities issued in the Offering. The Offering was conducted without any general solicitation or general advertising. The securities issued in the Offering have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
Item 8.01 - Other Events
36 words · Exhibit 99.1 attached
Item 8.01. Other Events On June 3, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1 · 1,010 words
EX-99.1 7 ex99-1.htm EX-99.1 Exhibit 99.1 SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules SALT LAKE CITY, Utah - June 3, 2026 - SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today announced that it has entered into securities purchase agreements with institutional and accredited investors pursuant to which the Company agreed to issue and sell an aggregate of 1,882,845 shares of common stock in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors (i) Class A Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock and (ii) Class B Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock. The warrants are exercisable immediately at an exercise price of $2.14 per share. The Class A Warrants will expire five years from the date of issuance and the Class B Warrants will expire two years from the date of issuance. The combined effective offering price for each share of common stock and accompanying warrants to be issued is $2.39. The offering is expected to close on or about June 3, 2026, subject to satisfaction of customary closing conditions. The aggregate gross proceeds to the Company from the private placement were $4.5 million before deducting fees and other offering expenses. Together with a previously completed $500,000 purchase of the Company’s common stock through its at-the-market offering program, the Company has raised approximately $5.0 million of equity capital in recent weeks. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital, commercialization activities, business development initiatives and other strategic opportunities. “We are pleased to complete this financing and appreciate the strong support from well known Life Science investors,” said Eric Olson, Chairman of the Board and Chief Executive Officer of SINTX Technologies. “We believe this transaction strengthens our balance sheet and enhances our ability to pursue our strategic objectives while continuing to advance the development and commercialization of our silicon nitride technology platform.” The shares of common stock and warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the warrants and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issued in the offering and the shares of common stock issuable upon exercise of the Class A Warrants and Class B Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. For more information on SINTX Technologies or its biomaterial platforms, visit www.sintx.com . About SINTX Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. With thousands of medical devices implanted since 2008 and nearly two decades of peer-reviewed research, SINTX has established itself as a leader in high-performance biomaterials that enhance clinical outcomes and patient safety. Supported by a strong patent portfolio, U.S.-based manufacturing, and strategic industry partnerships, the company continues to expand its technology platform through innovation and market diversification, including the recently FDA-cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions. These forward-looking statements include, without limitation, statements regarding the anticipated use of proceeds from the private placement, the Company’s ability to regain and maintain compliance with Nasdaq continued listing requirements, the filing and effectiveness of one or more registration statements covering the resale of securities issued in the private placement, future commercialization opportunities, development of new products and technologies, strategic initiatives, operational plans and future business prospects. Forward-looking statements are based on management’s current expectations, assumptions and projections and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a variety of risks and uncertainties, including, without limitation, risks related to market and economic conditions, the Company’s ability to maintain compliance with Nasdaq continued listing standards, the Company’s ability to obtain additional financing when needed, risks associated with commercialization of the Company’s technologies and products, the development of new product opportunities, regulatory developments, competition, changes in customer demand and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Risk Factors section of the Company’s Annual Report on Form 10-K filed with the SEC on March 20, 2026, and subsequent filings with the SEC. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release. SINTX Contacts: Investor Relations P: 801-839-3502 E: [email protected]
Item 9.01 - Financial Statements and Exhibits
72 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Class A Common Stock Purchase Warrant 4.2 Form of Class B Common Stock Purchase Warrant 10.1 Securities Purchase Agreement, dated June 2, 2026 10.2 Registration Rights Agreement, dated June 2, 2026 10.3 Partner Capital Agreement, dated April 6, 2026 99.1 Press Release dated June 3, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)